Loss of FAH activity in HT1 cells causes an accumulation of the upstream metabolite FAA in the liver and kidneys, the primary organs that express enzymes that are involved in tyrosine degradation.

BGB-16673 is an investigational oral BTK-targeted chimeric degradation activation compound. The Food and Drug Administration (FDA) has granted Fast Track designation to BGB-16673 for the treatment ...